These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31951561)

  • 1. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic.
    McCormick F
    Cancer Cell; 2020 Jan; 37(1):3-4. PubMed ID: 31951561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutics Targeting Mutant KRAS.
    Thein KZ; Biter AB; Hong DS
    Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. After decades, progress against an 'undruggable' cancer target.
    Kaiser J
    Science; 2019 Nov; 366(6465):561. PubMed ID: 31672875
    [No Abstract]   [Full Text] [Related]  

  • 6. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Covalent Inhibitor of KRAS
    Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
    J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
    Kirschner T; Müller MP; Rauh D
    J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mutant KRAS.
    Erlanson DA; Webster KR
    Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
    Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
    SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of GTPase KRAS
    Li Y; Yang L; Li X; Zhang X
    Expert Opin Ther Pat; 2024 Aug; 34(8):701-721. PubMed ID: 38884569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS G12C Inhibitors: Three Birds with One Stone.
    Seale T; Misale S
    Cancer Discov; 2024 May; 14(5):698-700. PubMed ID: 38692265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging strategies to target RAS signaling in human cancer therapy.
    Chen K; Zhang Y; Qian L; Wang P
    J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.